▎药明康德内容团队报道
[1]BioMarin Announces the Ministry of Health, Labor and Welfare (MHLW) in Japan Granted Approval for VOXZOGO® (vosoritide) for Injection for the Treatment of Children with Achondroplasia, Whose Growth Plates are Not Closed. Retrieved June 22, 2022, from https://investors.biomarin.com/2022-06-21-BioMarin-Announces-the-Ministry-of-Health,-Labor-and-Welfare-MHLW-in-Japan-Granted-Approval-for-VOXZOGO-R-vosoritide-for-Injection-for-the-Treatment-of-Children-with-Achondroplasia,-Whose-Growth-Plates-are-Not-Closed
[2] BioMarin Announces Favorable Results from Global Phase 2 Study of VOXZOGO™ (vosoritide) for Injection in Infants and Young Children with Achondroplasia at The Endocrine Society Annual Meeting, ENDO 2022 (June 11-14), in Atlanta. Retrieved June 13, 2022, from https://investors.biomarin.com/2022-06-13-BioMarin-Announces-Favorable-Results-from-Global-Phase-2-Study-of-VOXZOGO-TM-vosoritide-for-Injection-in-Infants-and-Young-Children-with-Achondroplasia-at-The-Endocrine-Society-Annual-Meeting,-ENDO-2022-June-11-14-,-in-Atlanta
[3] BioMarin Receives FDA Approval for VOXZOGO™ (vosoritide) for Injection, Indicated to Increase Linear Growth in Children with Achondroplasia Aged 5 and Up with Open Growth Plates. Retrieved November 19, 2021, from https://investors.biomarin.com/2021-11-19-BioMarin-Receives-FDA-Approval-for-VOXZOGO-TM-vosoritide-for-Injection,-Indicated-to-Increase-Linear-Growth-in-Children-with-Achondroplasia-Aged-5-and-Up-with-Open-Growth-Plates
本文来自药明康德内容团队,欢迎个人转发至朋友圈,谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「医药观澜」微信公众号留言联系我们。其他合作需求,请联系wuxi_media@wuxiapptec.com。
免责声明:药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的,文中观点不代表药明康德立场,亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导,请前往正规医院就诊。